Leukotriene B4 antagonist

Abstract: Leukotriene B₄ antagonists of the formula: wherein each symbol is as defined in the specification, processes for producing them, and pharmaceutical compositions containing them. The compounds of the present invention are very useful as the drugs for the treatment of allergic and inflammatory diseases.

Description: BACKGROUND OF THE INVENTION TECHNICAL FIELD The present invention relates to compounds effective as leukotriene B₄ antagonists. More particularly, this invention relates to leukotriene B₄ antagonists, to processes for producing them and to pharmaceutical compositions containing at least one of those leukotriene B₄ antagonists, which have excellent anti-leukotriene B₄ activity and are useful as an anti-allergic agent or an antiinflammatory agent. PRIOR ART In 1979 B. Sammuelsson reported the isolation and biological effects of leukotrienes (B. Sammuelsson et al. (1980): Advances in Prostaglandin and Thromboxane Research, Vol. 6. edited by B. Sammuelsson, R. Ramwell, and R. Paaletti, P. I. Raven Press, New York). Since then, a tremendous amount of research in the synthetic organic chemistry and pharmacology of leukotriene A₄, B₄, C₄, D₄, etc. has been performed. Leukotrienes induce an increase in capillary permeability and cause smooth muscle contraction. Leukotriene B₄, one of leukotrienes which is shown below, has different pharmacological properties from the others. It is chemotactic for macrophages and neutrophils at concentrations of∼1 ng/ml (greater than any other known lipid chemotactic factor). It is detected in the synovia of patients with rheumatoid arthritis or gouty arthritis, and in the sputum of obstructive airways diseases which suggest that it is a primary mediator of inflammatory and allergic states. In recent research some compounds having an antagonism on LTB₄ have been reported. For example, 1) EP-A-0183177 (SUMITOMO PHARMACEUTICALS CO.) 2) EP-A-276065 (ELI LILLY & CO) 3) EP-A-276064 (ELI LILLY & CO) 4) EP-A-0405116 (ONO PHARMACEUTICAL CO) 5) EP-A-292977 (SEARLE G D & CO) 6) WO-A-8805045 (UPJOHN CO) 7) JP-A-01 29 363 (Yoshitomi Pharmaceutical Co.) (phenoxyalkyl) piridines SUMMARY OF THE INVENTION In accordance with the present invention, leukotriene B₄ antagonists of the following general formula [I] and their non-toxic pharmaceutically acceptable salts are provided, which have potent anti-leukotriene B₄ activity which include suppression of chemotaxis, degranulation and O₂-production of leukocytes, and modulation of lymphocytes activity. This action may render these compounds very useful as the drugs for the treatment of inflammatory states or immunological disorders such as allergy, rheumatoid arthritis, inflammatory bowel disease. DISCLOSURE OF THE INVENTION The novel leukotriene B₄ antagonists provided by the present invention are those represented by the formula [I]: wherein B is a pyridinediyl group; R¹ is a C₁-C₅ alkyl group; R² is a hydroxyl group or a C₁-C₅ alkoxy group; R³ and R⁴ are each independently a hydrogen atom, a C₁-C₅ alkyl group, a C₂-C₅ alkenyl group or a C₂-C₅ alkynyl group; R⁵ is a hydrogen atom, a C₁-C₅ alkyl group or a hydroxy C₁-C₅ alkyl group; R⁶ is a CH₂ (CH₂) n COOH group, wherein n is 0, 1, 2, 3, 4 or 5; or a pharmaceutically acceptable salt thereof. In the definitions as used above, the term "C₁-C₅ alkyl" means a straight or branched chain C₁-C₅ alkyl (e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl). The term "C₂-C₅ alkenyl" means a straight or branched chain C₂-C₅ alkenyl (e.g. 1-methylethenyl, 1-ethylethenyl, 1-propenyl, 2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1-n-butenyl, 2-n-butenyl, 3-n-butenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl and 4-pentenyl). The term "C₂-C₅ alkynyl" means a straight or branched chain C₂-C₅ alkynyl (e.g. ethynyl, 1-propynyl, 2-propynyl, 1-methyl-2-propynyl, 1-n-butynyl, 2-n-butynyl, 3-n-butynyl, 3-methyl-1-butynyl, 1-methyl-2-butynyl, 2-methyl-3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl and 4-pentynyl). The term "C₁-C₅ alkoxy" means alkoxy having C₁-C₅ alkyl moiety (e.g. methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, iso-pentoxy, sec-pentoxy and neo-pentoxy). The term "6 membered heteroaromatic group which is constituted by carbon atoms and one or two nitrogen atoms" includes pyridinediyl, pyrazinediyl and pyrimidinediyl. The term "monocyclic 5∼6 membered heteroaromatic group" contains, for example, 1-3 hetero atoms which can be a nitrogen, oxygen or sulfur atom, or an oxydized nitrogen atom (N →0), and examples of the monocyclic 5-6 membered heteroaromatic group are a pyridinediyl group and any one of the group of the formula (i)-(viii): A basic object of the present invention is to provide novel compounds effective as leukotriene B₄ antagonists [I] having excellent pharmacological activities. Another object of the present invention is to provide processes for producing those compounds [I]. A further object of the present invention is to provide a pharmaceutical composition containing a compound of the formula [I]. These and other objects will be apparent to those skilled in the art to which the present invention pertains from the foregoing and subsequent descriptions. The novel leukotriene B₄ antagonists [I] of the invention can be prepared by the following method : (wherein B, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above, R¹¹ is the same as R⁶, but it does not mean free carboxylic group; R¹² is a group of the formula: CH₂ (CH₂) n COOR 7' wherein R 7' is a benzyl group, a C₁-C₅ alkyl group or a C₁-C₅ alkyl group substituted with an aminoheteroaromatic group wherein the heteroaromatic group is a monocyclic 5-6 membered heteroaromatic group, R¹, R², R³, R⁴, R⁵ and B are as defined above and n is 0, 1, 2, 3, 4 or 5. Method A The amide compound [IV] can be prepared from an acid compound [II] by reacting an amine compound [III] in the presence of a condensing agent (e.g. dicyclohexyilcarbodiimide or ethyldimethylaminopropylcarbodiimide hydrochloride), hydroxybenzotriazole and a tertiary amine (e.g. triethylamineor 4-dimethylaminopyridine) in an inert solvent (e.g. dichloromethane, mixed solvent of dichloromethane and N,N-dimethylformamide) at a temperature in the range from 0°C to the boiling temperature of the solvent. Method B The amide compound [IV] can be obtained from an acid chloride or an acid anhydride of an acid compound [II] by reacting with an amine compound [III] or [VIII] in the presence of a tertiary amine (e.g. triethylamine), or by reacting with a salt of an amine compound [III] (e.g. sodium salt or potassium salt) in the absence of amine in an inert solvent (e.g. tetrahydrofuran) at a temperature in the range from 0 °C to a boiling temperature of the solvent. The transformation of an acid group to an acid chloride group can be carried out by treating the acid compound with phosphorous oxychloride or thionyl chloride in an inert solvent (e.g. chloroform) or in the absence of solvent at a temperature in the range of from -40°C to the boiling temperature of the reaction mixture. The transformation of an acid group to an acid anhydride group can be carried out by treating the acid compound with chloroformate ester (e.g. ethyl chloroformate) in the presence of a tertiary amine (e.g. triethylamine) in an inert solvent (e.g. chloroform) at a temperature in the range of from -40 °C to the boiling temperature of the solvent. Method C The acid compound [VI] can be prepared by hydrolysis of the ester compound [V] by treating with an aqueous alkali (e.g. sodium hydroxide, lithium hydroxide) in an inert solvent (e.g. tetrahydrofuran, methanol, or ethanol). Method D The amine compounds [III] are known compounds or easily obtained as described in e.g. J. Goto, K. Sakane, Y. Nakai, T. Teraji, The journal of antibiotics, 37 , 532 (1984), I. Csendes, B. W. Müller, W. Tosch, The journal of antibiotics, 36 , 1020 (1983), M. Ohta, Yakugaku zassi, 72 , 1536 (1983), JP-A-58-23697. And, the starting compounds [II], [II-1] and [II-2] can be obtained by the following method. (wherein B, R¹, R², R³ and R⁴ are as defined above, R¹⁷ is a C₁-C₅ alkyl group, R¹⁸ is a C₁-C₅ alkyl group, Hal is a chlorine or bromine atom) Alkylation of the compound [XV] into the compound [XVII] can be accomplished by treating the former with the compound [XVI] in an inert solvent (e.g. N,N-dimethylformamide) in the presence of a base (e.g. anhydrous potassium carbonate, ). Optionally, the compound [XVII] can be alkylated to produce the compound [XVIII] by the same procedure as used in the synthesis of the compound [XVII] from the compound [XV]. And, the compound (II-1) and (II-2), respectively, can be prepared from the compound [XVII] and [XVIII] by hydrolysis (Method C). The compound [XV] is a known compound or easily obtained as described in e.g. J. Hurst, J. Wibberley, Journal of Chemical Society, 1962 , 119. The compound [XVI] is a known compound or can easily be obtained. Specific examples of the leukotriene B₄ antagonists are as follows: Among the leukotriene B₄ antagonists thus obtained, the compound [I] can be converted to a pharmaceutically acceptable salt form. The pharmaceutically acceptable salts of these leukotriene B₄ antagonists can be formed with pharmaceutically acceptable metal cation such as sodium, potassium, magnesium and calcium, ammonium or amine cations. The preparations of pharmaceutical compositions can be carried out by conventional methods. For example, leukotriene B₄ antagonists [I] may be mixed with carriers, diluents, lubricants, fillers and/or binders such as lactose, sucrose, calcium phosphate, starch, talcum, casein, magnesium stearate, methyl cellulose, polyglycols and tragacanth, sometimes together with stabilizers and emulsifying agents. The resulting mixture may be processed in a usual manner to tablets, capsules, pills, injections, ointment and suppositories. In a clinical practice, the leukotriene B₄ antagonists [I] can be administered orally, intranasallyl or intradermally. The daily dosage may vary depending upon the administration route, symptom, age or weight of the patient, and the usual oral dosage of the active ingredient is between 1 mg and 1000 mg daily for human beings. DESCRIPTION OF THE PREFERED EMBODIMENTS Practical and prefered embodiments of the present invention are illusturated in the following examples, which are not intended to limit the scope of the invention. Reference Example 1 5-Ethyl-2,4-dihydroxyacetophenone (0.97 g, 5.0 mmol) and methyl 6-bromomethylpyridine-2-carboxylate (1.38 g, 5.8 mmol) were dissolved in an N,N-dimethylformamide solution (50 ml), and anhydrous potassium carbonate (480 mg) was added to the above solution, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was poured into water and extracted with ethyl acetate (100 ml ×3). The extract was dried, concentrated and chromatographed on silica gel to give methyl 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylate. Reference Example 2 Methyl 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy) methyl]pyridine-2-carboxylate (38 mg, 12 mmol) was dissolved in a methanol solution (2 ml), and one normal sodium hydroxide (1 ml) was added to the above solution at 0 °C, and the mixture was stirred at room temperature for 1 hour. One-tenth normal potassium bisulfate was titrated to the above solution until it became pH2. Then, precipitated white crystals were filtered off, and washed with water, and dried to give 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylic acid. Reference Example 3 3-n-Propyl-2,4-dihydroxyacetophenone (816 mg, 4.2 mmol) was added to a methanol solution (10 ml), sodium metal was added to the solution at 0°C, and the mixture was stirred for 30 min, and evaporated under reduced pressure, and dried to give a sodium salt of 3-n-propyl-2.4-dihydroxyacetophenone. The salt was dissolved in N,N-dimethylformamide (10 ml), and it was added to a N,N-dimethylformamide solution (10 ml) of methyl-6-bromomethylpyridine-2-carboxylate (920 mg, 4.0 mmol) at room temperature, and the mixture was stirred for 1 hour. The reaction mixture was poured into water, and normal potassium bisulfate was titrated until it became pH3, and extracted with ethyl acetate (100 ml×3). The extract was dried, concentrated and chromatographed on silica gel to give methyl 6-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]pyridine-2-carboxylate. Reference Example 4 According to the procedure of Reference Example 2, 6-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]pyridine-2-carboxylic acid was obtained by hydrolysis of methyl 6-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]pyridine-2-carboxylate. Reference Example 5 Anhydrous potassium carbonate (1.0 g) was added to a N,N-dimethylformamide solution (10 ml) of methyl 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylate (500 mg, 1.4 mmol) and methyliodide (5 ml),and the mixture was stirrered at 70°C for 2 hours. The reaction mixture was poured into water and extracted with ethylacetate and washed with saturated aqueous sodium chloride. Then, the extract was dried, concentrated and chromatographed on silica gel to give methyl 6-[(4-acetyl-2-ethyl-5-methoxyphenoxy)methyl]pyridine-2-carboxylate. Reference Example 6 According to the procedure of Reference Example 2, 6-[(4-acetyl-2-ethyl-5-methoxyphenoxy)methyl]pyridine-2-carboxylic acid was obtained by hydrolysis of methyl 6-[(4-acetyl-2-ethyl-5-methoxyphenoxy)methyl]pyridine-2-carboxylate. Reference Example 7 According to the procedure of Reference Example 5, methyl 6-[(4-acetyl-2-n-propyl-3-methoxyphenoxy) methyl]pyridine-2-carboxylate was obtained from methyl 6-[(4-acetyl-3-hydroxy-2-n-propylphenoxy)methyl]pyridine-2-carboxylate. Reference Example 8 According to the procedure of Reference Example 2, 6-[(4-acetyl-2-n-propyl-3-methoxyphenoxy)methyl]pyridine-2-carboxylic acid was obtained by hydrolysis of methyl 6-[(4-acetyl-2-n-propyl-3-methoxyphenoxy)methyl]pyridine-2-carboxylate. ¹H-NMR δ ppm 1 (solvent: CDCL₃) 0.99(3H, t, J=7.4Hz), 1.62(2H, tq, J=7.4Hz, J=7.4Hz), 2.57(3H, s), 2.76(2H, t, J=7.4Hz), 4.04(3H, s), 5.39(2H, s), 6.46(1H, d, J=8.9Hz), 7.59(1H, d, J=8.9Hz), 7.79(1H, d, J=6.6Hz), 7.92(1H, dd, J=6.6Hz), J=7.9Hz), 8.10(1H, d, J=7.9Hz) 2 (solvent: CDCL₃) 1.26(3H, t, J=7.6Hz), 2.59(3H, S), 2.68(2H, q, J=7.6Hz), 5.30(2H, s), 6.43(1H, s), 7.51(1H, s), 7.78(1H, d, J=6.9Hz), 8.04(1H, dd, J=6.9Hz, J=7.9Hz), 8.22(1H, d, J=7.9Hz) 3 (solvent: CDCL₃) 0.99(3H, t, J=7.4Hz), 1.62(2H, tq, J=7.4Hz, J=7.4Hz), 2.57(3H, s), 2.76(2H, t, J=7.4Hz), 4.04(3H, s), 5.39(2H,s), 6.46(1H, d, J=8.9Hz), 7.59(1H, d, J=8.9Hz), 7.79(1H, d, J=6.6Hz), 7.92(1H, dd, J=6.6Hz, J=7.9Hz), 8.10(1H, d, J=7.9Hz) 4 (solvent: CDCL₃) 0.99(3H, t, J=7.4Hz), 1.62(2H, tq, J=7.4Hz, J=7.4Hz), J=7.4Hz), 2.57(3H, s), 2.76(2H, t, J=7.4Hz), 5.34(2H, s), 6.45(1H, d, J=8.9Hz), 7.60(1H, d, J=8.9Hz), 7.79(1H, dd, J=1.0Hz, J=6.9Hz), 8.04(1H, dd, J=6.9Hz, J=7.4Hz), 8.21(1H, dd, J=1.0Hz, J=7.4Hz) ¹H-NMR δ ppm 5 (solvent: CDCL₃) 1.24(3H, t, J=7.5Hz), 2.58(3H, s), 2.70(2H, q, J=7.6Hz), 3.86(3H, s), 4.04(3H, s), 5.40(2H, s), 7.72(1H,s), 7.79(1H, d, J=7.9Hz), 7.94(1H, dd, J=7.9Hz, J=7.6Hz), 8.11(1H, d, J=7.6Hz) 6 (solvent: CDCL₃) 1.24(3H, t, J=7.4Hz), 2.57(3H, s), 2.69(2H, q, J=7.4Hz), 3.90(3H, s), 5.40(2H, s), 6.64(1H, s), 7.65(1H, s), 7.80(1H, d, J=7.3Hz), 8.01(1H, dd, J=7.6Hz, J=7.6Hz), 8.13(1H, d, J=7.9Hz) 7 (solvent: CDCL₃) 1.02(3H, t, J=7.5Hz), 1.66(2H, q, J=7.6Hz), 2.61(3H, s), 2.75(2H, t, J=7.8Hz), 3.78(3H, s), 5.31(2H, s), 6.70(1H, d, J=8.6Hz), 7.56(1H, d, J=8.9Hz), 7.90(1H, d, J=7.6Hz, J=7.9Hz), 8.04(1H, dd, J=7.6Hz, J=7.9Hz), 8.21(1H, d, J=7.6Hz) 8 (solvent: CDCL₃) 1.02(3H, t, J=7.6Hz), 1.65(2H, q, J=7.7Hz), 2.62(3H, s), 2.75(2H, t, J=7.8Hz), 3.78(3H, s), 5.31(2H, s), 6.70(1H, d, J=8.6Hz), 7.56(1H, d, J=8.9Hz), 7.90(1H, d, J=7.9Hz), 8.04(1H, dd, J=7.6Hz, J=7.9Hz), 8.21 (1H, d, J=7.6Hz) Reference Example 9 A mixture of 6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxylic acid (63 mg, 0.20 mmol), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (40 mg, 0.20 mmol), 1-hydroxybenzotriazole (30 mg, 0.22 mmol), 2-aminothiazole-4-carboxamide (35 mg, 0.24 mg) and triethylamine (20 mg, 0.20 mmol) in a mixed solution of dichloromethane (2 ml) and N,N-dimethylformamide (2 ml) was stirred at room temperature for 44 hours. The reaction mixture was poured into water and extracted with ethyl acetate (80 ml×3). The extract was dried over anhydrous magnesium sulfate, concentrated under reduced pressure and chromatographed on silica gel to give 2-[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)-methyl]pyridine-2-carboxamide]thiazol-4-ylcarboxamide. Reference Examples 10 - 15 According to the procedure of Reference Example 9, the Reference compounds 10 - 15 were obtained. Reference Example 16 Ethyl 2-[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl] pyridine-2-carboxamide]thiazole-4-ylcarboxylate (24 mg, 0.05 mmol) was suspended in methanol (1.5 ml), followed by addition of one-second normal sodium hydroxide (1.0 ml). After the solution was stirred for 2 hr, it was made acidic with one-second normal potassium blsulfate. Precipitated crystals were separated by filtration, and washed with water, and dried to give 2-[6-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]pyridine-2-carboxamide]thiazol-4-ylcarboxylic acid. Example 1 - 5 According to the procedure of Reference Example 16, the title compounds were obtained. ¹H-NMR δ ppm 9 (solvent: CDCL₃) 1.28(3H, t, J=7.6Hz), 2.60(3H, s), 2.71(2H, q, J=7.6Hz), 5.34(1H, s), 5.55(1H, bs), 6.48(1H, s), 7.05(1H, bs), 7.52(1H, s), 7.77(1H, d, J=7.3Hz), 9.90(1H, s), 8.04(1H, dd, J=6.6Hz, J=7.3Hz), 8.28(1H, d, J=7.3Hz), 10.98(1H, bs), 12.70(1H, s) 10 (solvent: CDCl₃) 1.26(3H, t, J=7.6Hz), 1.32(3H, t, J=7.3Hz), 2.58(3H, s), 2.68(2H, q, J=7.6Hz), 4.2-4.3(4H, m), 5.26(2H, s), 6.45(1H, s), 7.49(1H, s), 7.64(1H, d, J=7.6Hz), 7.92(1H, dd, J=6.9, 7.6Hz), 8.15(1H, d, J=6.9Hz), 12.66(1H, s) 11 (solvent: CDCl₃) 1.25(3H, t, J=7.6Hz), 1.28(3H, t, J=7.3Hz), 2.6-2.7(4H, m), 3.7-3.8(2H, m), 4.1-4.2(2H, q, J=7.3Hz), 5.24(2H, s), 6.45(1H, s), 7.49(1H, s), 7.61(1H, d, J=7.9Hz), 7.90(1H, dd, J=6.6, 7.9Hz), 8.14(1H, d, J=6.6Hz), 8.42(1H, br), 12.66(1H, s) 12 (solvent: CDCl₃) 1.25(3H, t, J=7.6Hz), 1.9-2.1(2H, m), 2.45(2H, t, J=7.6Hz), 2.58(3H, s), 2.68(2H, q, J=7.6Hz), 3.54(2H, m), 3.68(3H, s), 5.25(2H, s), 6.47(1H, s), 7.50(1H, s), 7.61(1H, d, J=7.6Hz), 7.90(1H, dd, J=7.6Hz, J=7.9Hz), 8.10(1H, br), 8.15(1H, d, J=7.9Hz) 13 (solvent: CDCl₃) 1.25(3H, t, J=7.6Hz), 1.3-1.5(2H, m), 1.6-1.8(4H, m), 2.34(2H, t, J=7.6Hz), 2.58(3H, s), 2.68(2H, q, J=7.6Hz), 3.4-3.5(2H, m), 3.67(3H, s), 5.25(2H, s), 6.47(1H, s), 7.49(1H, s), 7.51(1H, d, J=7.9Hz), 7.90(1H, dd, J=7.9Hz, 7.9Hz), 8.02(1H, br), 8.16(1H, d, J=7.9Hz), 12.67(1H, s) ¹H-NMR δ ppm 14 (solvent: CDCl₃) 1.22(3H, t, J=6.9Hz), 1.25(3H, t, J=7.1Hz), 1.29(3H, t, J=7.1Hz), 2.57(3H, s), 2.68(2H, q, J=7.4Hz), 2.78(1H, t, J=7.1Hz), 3.44(1H, q, J=7.1Hz), 3.58(1H, q, J=7.1Hz), 3.70(1H, t, J=7.4Hz), 3.79(1H, t, J= 7.4Hz), 4.10(1H, q, J=7.1Hz), 4.18(1H, q, J=7.1Hz), 5.21(1H, s), 5.23(1H, s), 6.43(1H, s), 7.48(1H, s), 7.5-7.9(3H, m), 2.84(1H, t, J=7.1Hz) 15 (solvent: CDCL₃) 1.27(3H, t, J=7.6Hz), 1.43(3H, t, J=7.1Hz), 2.59(3H, s), 2.70(2H, q, J=7.6Hz), 4.45(2H, q, J=7.1Hz), 5.28(1H, s), 6.43(1H, s), 7.52(1H, s), 7.73(1H, d, J=7.9Hz), 7.94(1H, d, J=0.7Hz), 8.01(1H, t, J=7.9Hz), 8.25(1H, d, J=7.9Hz), 11.32(1H, bs), 12.66(1H, s) 16 (solvent: DMSO-d₆) 1.20(3H, t, J=7.6Hz), 2.59(3H, s), 2.63(2H, q, J=7.6Hz), 5.44(2H, s), 6.71(1H, s), 7.45(1H, s), 7.66(1H, S), 7.7-7.8(1H, m), 8.10-8.20(2H, m), 12.60(1H, bs) ¹H-NMR δ ppm 1 (solvent: d₆-DMSO) 1.18(3H, t, J=7.6Hz), 2.58(3H, S), 2.62(2H, q, J=7.6Hz), 4.00(2H, d, J=5.9Hz), 5.36(2H, s), 6.57(1H, s), 7.69(1H, s), 7.73(1H, d, J=6.3Hz), 8.01(1H, d, J=6.3Hz), 8.10(1H, dd, J=6.3Hz, 6.3Hz), 8.88(1H, t, J=5.9Hz), 12.55(1H, s) 2 (solvent: d₆-DMSO) 1.18(3H, s, J=7.6Hz), 2.58(3H, s), 2.61(2H, q, J=7.6Hz), 2.69(2H, q, J=7.6Hz), 3.4-3.5(2H, m), 5.35(2H, s), 6.57(1H, s), 7.69(1H, s), 7.70(1H, dd, J=1.0Hz, 7.6Hz), 7.99(1H, dd, J=1.0Hz, 7.6Hz), 8.07(1H, dd, J=7.6Hz, 7.6Hz), 8.72(1H, t, J=5.9Hz), 12.54(1H, br) 3 (solvent: d₆-DMSO) 1.18(3H, t, J=7.6Hz), 1.7-1.8(2H, m), 2.26(2H, t, J=7.6Hz), 2.58(3H, s), 2.62(2H, q, J=7.6Hz), 3.3-3.5(2H, m), 5.36(2H, s), 6.57(1H, s), 7.69(1H, s), 7.70(1H, d, J=7.6Hz), 7.98(1H, d, J=7.6Hz), 8.06(1H, dd, J=7.6Hz, 7.6Hz), 8.68(1H, d, J=5.6Hz), 12.00(1H, br), 12.55(1H, br) 4 (solvent: DMSO-d₆) 1.18(3H, t, J=7.6Hz), 1.2-1.3(2H, m), 1.5-1.7(4H, m), 2.21(2H, t, J=7.3Hz), 2.58(3H, s), 2.62(2H, q, J=7.6Hz), 5.36(2H, s), 6.57(1H, s), 7.68(1H, d, J=7.6Hz), 7.69(1H, s), 7.98(1H, d, J=7.6Hz), 8.06(1H, dd, J=7.6Hz, 7.6Hz), 8.61(1H, m), 12.55(1H, br) 5 (solvent: CD₃OD/CDCl₃(1/4)) 1.2-1.3(6H, m), 2.57(1H, s), 2.67(2H, q, J=7.5Hz), 2.8-3.0(2H, m), 3.4-3.8(4H, m), 5.24(2H, s), 6.4-6.5(1H, m), 7.48(1H, s), 7.5-.7.7(2H, m), 7.85(1H, dd, J=7.6, 7.9Hz),

Claims: Claims for the following Contracting States : AT, BE, CH/LI, DE DK, FR, GB, IT, NL, PT, SE, GR A compound represented by the formula : wherein B is a pyridinediyl group; R¹ is a C₁-C₅ alkyl group; R² is a hydroxyl group or a C₁-C₅ alkoxy group; R³ and R⁴ are each independently a hydrogen atom, a C₁-C₅ alkyl group, a C₂-C₅ alkenyl group or a C₂-C₅ alkynyl group; R⁵ is a hydrogen atom, a C₁-C₅ alkyl group or a hydroxy C₁-C₅ alkyl group; R⁶ is a CH₂ (CH₂) n COOH group, wherein n is 0, 1, 2, 3, 4 or 5; or a pharmaceutically acceptable salt thereof. The compound according to claim 1, wherein R¹ is a methyl group and R² is a hydroxyl group. The compound according to claim 1, wherein R³ is a hydrogen atom. The compound according to claim 1, wherein R¹ is a methyl group, R² is a hydroxyl group and R³ is a hydrogen atom. The compound according to claim 4, wherein B is a 2,6-pyridinediyl group. The compound according to any of claims 1-5, wherein R⁴ is an ethyl group. The compound according to any of claims 1-6, wherein R⁶ is a CH₂CH₂CO₂H group. A compound according to claim 1 , which has the formula: A compound according to claim 1 , which has the formula: A compound according to claim 1 , which has the formula: A compound according to claim 1 , which has the formula: A compound according to claim 1 , which has the formula: A process for producing a compound as claimed in claim 1 which comprises: hydrolyzing a compound of the formula: wherein R¹² is a group of the formula: CH₂ (CH₂) n COOR 7' wherein R 7' is a benzyl group, a C₁-C₅ alkyl group or a C₁-C₅ alkyl group substituted with an aminoheteroaromatic group wherein the heteroaromatic group is a monocyclic 5-6 membered heteroaromatic group and R¹, R², R³, R⁴, R⁵, n and B are as defined in Claim 1. A pharmaceutical composition useful as an antiinflammatory agent or an antiallergic agent, which comprises an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutiacally acceptable carrier or diluent. A process for producing a pharmaceutical composition useful as an antiinflammatory agent or an antiallergic agent, which comprises mixing an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient with a pharmaceutiacally acceptable carrier or diluent. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating inflammatory or allergic states. A compound of claim 1 for use as a medicament as an active therapeutic substance. Claims for the following Contracting State : ES A process for producing a compound represented by the formula : wherein B is a pyridinediyl group; R¹ is a C₁-C₅ alkyl group; R² is a hydroxyl group or a C₁-C₅ alkoxy group; R³ and R⁴ are each independently a hydrogen atom, a C₁-C₅ alkyl group, a C₂-C₅ alkenyl group or a C₂-C₅ alkynyl group; R⁵ is a hydrogen atom, a C₁-C₅ alkyl group or a hydroxy C₁-C₅ alkyl group; R⁶ is a CH₂ (CH₂) n COOH group, wherein n is 0, 1, 2, 3, 4 or 5; or a pharmaceutically acceptable salt thereof, which process comprises hydrolyzing a compound of the formula: wherein R¹² is a group of the formula: CH₂ (CH₂) n COOR 7' wherein R 7' is a benzyl group, a C₁-C₅ alkyl group or a C₁-C₅ alkyl group substituted with an aminoheteroaromatic group wherein the heteroaromatic group is a monocyclic 5-6 membered heteroaromatic group and R¹, R², R³, R⁴, R⁵, n and B are as defined above. The process according to claim 1, wherein R¹ is a methyl group and R² is a hydroxyl group. The process according to claim 1, wherein R³ is a hydrogen atom. The process according to claim 1, wherein R¹ is a methyl group, R² is a hydroxyl group and R³ is a hydrogen atom. The process according to claim 4, wherein B is a 2,6-pyridinediyl group. The process according to any of claims 1-5, wherein R⁴ is an ethyl group. The process according to any of claims 1-6, wherein R⁶ is a CH₂CH₂CO₂H group. A process according to claim 1 , wherein the produced compound has the formula: A process according to claim 1 , wherein the produced compound has the formula: A process according to claim 1 , wherein the produced compound has the formula: A process according to claim 1 , wherein the produced compound has the formula: A process according to claim 1 , wherein the produced compound has the formula: A process for producing a pharmaceutical composition useful as an antiinflammatory agent or an antiallergic agent, which comprises mixing an effective amount of a compound as produced in accordance with claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient with a pharmaceutiacally acceptable carrier or diluent.

Inventors: KAWAKAMI HAJIME, NAGATA HIDEO, KAWAKAMI, HAJIME, NAGATA, HIDEO
Applicants: SUMITOMO PHARMA, SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
Application year: 1992
Main classification: C07D213
IPC codes: C07D417, A61P29, C07D213, A61K31, C07D401, C07C235, A61P17, C07D241, C07C321, C07D413, A61P1, C07D277, A61P37, C07C237, C07C279, A61P43, A61P19